Aurobindo arm terminates paediatric pentavalent vax licence pact with Hilleman Labs

HYDERABAD: Nearly a year and a half after its subsidiary Auro Vaccines Pvt Ltd inked a licencing pact with Hilleman Laboratories Singapore Pte Ltd to develop, manufacture and commercialise a paediatric pentavalent vaccine candidate, the company has terminated the deal.
Pointing out that the deal was terminated on March 5, 2025, Aurobindo Pharma said that as Auro Vaccines is not a material subsidiary to the company, the termination was not expected to have any material impact on the company.
“The termination of a licence agreement for a very early stage vaccine asset is not a material event,” the company said in a regulatory filing.
“It may also be noted that this termination of agreement will not have any significant impact on the company and its subsidiaries or its financials. In the event of any significant impact in future, we will keep the exchanges informed about the same and provide necessary disclosures,” it said.
As per the agreement inked in September 2023, Auro Vaccines was to make milestone payments to the Singapore-based company upon achieving certain development and clinical study outcomes. As part of the deal, Auro Vaccines was also to pay royalties to Hilleman once the vaccine candidate was commercialised.